With Dupixent's Patent Clock Ticking, Sanofi Circles Insmed
Vandana SinghBenzinga Staff Writer November 19, 2026, 1:57 PM ETNov 19, 1:57 PM ET3 min read3 min
SNYSanofi SA
$46.15-2.07%
Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
Reveal Full Score Edge Rankings
MomentumN/A
Growth10.18
Quality18.70
Value34.44
Price Trend
ShortMediumLongOverview INSMInsmed Inc
$141.9718.5%
Insmed Inc. (NASDAQ:INSM) stock surged Thursday following a report that French pharmaceutical giant Sanofi SA (NASDAQ:SNY) is exploring a potential acquisition of the respiratory disease specialist.
The potential acquisition comes as Sanofi seeks new growth opportunities to reduce its reliance on blockbuster drug Dupixent.
Sanofi Explores Potential Insmed Takeover
Bloomberg reported Thursday that Sanofi is considering acquiring Insmed as it searches for its next blockbuster treatment under new CEO Belén Garijo .
Citing people familiar with the matter, the report…